|Bid||0.1900 x 0|
|Ask||0.2000 x 0|
|Day's Range||0.1900 - 0.2000|
|52 Week Range||0.0350 - 0.5200|
|Beta (5Y Monthly)||1.22|
|PE Ratio (TTM)||100.00|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
TORONTO, Oct. 05, 2020 (GLOBE NEWSWIRE) -- (TSX Venture:FTI) FTI Foodtech International Inc. ("FTI") announces that it intends to arrange a private placement for up to $600,000. The proposed private placement would be a non-brokered offering of 2,000,000 units of the Issuer, (the “Units”), at a price of $0.30 per Unit. Each Unit will be comprised of one Common Share and one common share purchase warrant (a “Warrant”), each Warrant being exercisable to acquire one Common Share at a price of $0.50 per Common Share for a period of one (1) year following the closing date of the private placement.The proceeds will be used for costs related to sales and marketing of PPE supplies and the Rapid-Result Serological COVID-19 Antibody Test Kit, to evaluate other opportunities, to cover the company’s operating expenses and to reduce company debt. A further press release will be issued once the financing has been completed.The TSX Venture Exchange Inc. has not approved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CONTACT: For further information, contact: William Hullah, President, FTI at (416) 444-1058.
FTI Foodtech International Inc. (V.FTI) hit a new 52-week high of 44 cents on Friday. FTI Foodtech International ...
TORONTO, Oct. 02, 2020 (GLOBE NEWSWIRE) -- (TSX Venture: FTI) -- FTI Foodtech International Inc. ("FTI") has obtained a letter of authorization from Rapid Virus Detect Ltd. - a medical device importer and distributor in British Columbia - for marketing, sales and after-sales services of their rapid-result, serological COVID-19 Antibody Test Kit, worldwide. This COVID-19 (SARS-Co-V-2) IgM/IgG Antibody Test Kit is manufactured by Wuhan EasyDiagnosis Biomedicine Co., Ltd of Wuhan, China. The kit, which provides qualitative detection of anti-SARS-CoV-2 IgM and IgG antibody in human serum, plasma and whole blood, is a nucleic acid extraction reagent test for use by health professionals. The test kit will detect the immunoglobulin IgM (the fast-acting antibody) and the immunoglobulin IgG (the long-lasting antibody) within 15 minutes and will function as a screening test for COVID-19. Health Canada review for approval is in progress. CE IVD Certified. ISO Certified. Approved by China National Drug Administration.FTI continues to market a variety of products, including disposable and fabric face masks, face shields, goggles, hand sanitizers and thermometers to meet the need for personal protective equipment (PPE) and safety supplies aimed at minimizing the spread of COVID-19. Certification is indicated by product. Visit the online store at fti.ppebrand.com.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.For further information, contact: William Hullah, President, FTI at (416) 444-1058.